

UBS Investment Research

Asian Equity Strategy: India to neutral

Equity Strategy

19 March 2007

www.ubs.com/investmentresearch

Sakthi Siva

Strategist
sakthi.siva@ubs.com
+65-6836 5916

Kin Nang Chik

Associate Strategist
kin-nang.chik@ubs.com
+852-2971 8636

From underweight on improved valuations

■ SENSEX down 14% from high, YTD 2nd worst performer

We are upgrading India from underweight to neutral for 4 reasons. 1. Valuations - premium on P/ BV vs ROE has dropped to just 5%, the lowest since Sep 2004. 2. Dropped out of the expensive 4 club. 3. Strong consensus EPS upgrades on a strong base of EPS growth. 4. Approaching the average EMBI sell-off of 23 trading days.

■ India's premium 5%, the lowest since Sep 2004

While historic PE at 16.2x is still some 10% above the historical average (see chart below to the right), India's premium to the region has dropped from 31% at end Oct 06 to 5% currently. The premium has dropped as the SENSEX is YTD the 2nd worst performer (SENSEX -8.5% US\$ vs -1.6% for region) but consensus EPS revisions remain strong.


■ Strong EPS revisions on strong EPS growth

Chart 1 highlights that 2007E consensus EPS for India is up 10% since 31 Dec 2005. Significantly, there were big upgrades in recent months - Feb was +2.4%, March to date +0.6%. Some investors argue that since other markets have also seen strong EPS upgrades - Philippines +20%, Singapore +19%, Malaysia +10%.

■ 2007 bottom up is for India's EPS to grow by 26%


India's EPS upgrades imply 26% EPS growth in 2007 and 23% in 2008. This compares with Singapore's 6% (or 13% after one-offs), Philippines 15% and Malaysia's 17% in 2007.

India P/ BV vs ROE relative to the region



Source: UBS estimates

Chart 1: India historic PE



Source: Datastream, UBS estimates

This report has been prepared by UBS Securities Pte. Ltd.

ANALYST CERTIFICATION AND REQUIRED DISCLOSURES BEGIN ON PAGE 4

UBS does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

4 reasons why we are upgrading India from Underweight to Neutral

We are upgrading India from Underweight to Neutral for 4 reasons:

One, valuations – on P/ BV vs ROE relative to the region, India’s premium has dropped to just 5%. This is down from a recent high of 31% at end October 2006. **The 5% premium is the lowest since September 2004.** India’s premium has dropped because of the SENSEX’s poor performance (for example, YTD in US\$, the SENSEX is down 8.4% versus -1.6% for MSCI Asia Pacific ex Japan in US\$) and continued consensus EPS upgrades (see below).

1st reason – P/ BV vs ROE premium just 5%, lowest premium since Sep 2004


Two, India has dropped out of the expensive 4 club. Chart 1 highlights that India is no longer amongst the four most overvalued markets on P/ BV vs ROE relative to the region. The last time this occurred was in June 2006.

2nd reason – India has dropped out of the expensive 4 club

Three, with the SENSEX being a EMBI driven market, chart 2 and Table 1 highlight that the **EMBI sell-off now in its 17th day is fast approaching the average sell-off of 23 trading days.**


3rd reason – approaching the average EMBI sell-off

Chart 1: Countries on P/ BV vs ROE relative to the region



Source: UBS estimates

Chart 2: EMBI spreads



Source: J P Morgan, Bloomberg, UBS estimates

Table 1: Last 4 sell-offs in EMBI spreads


Low in EMBI	High in EMBI	Rise in EMBI	Length of sell-off
13-Apr-04	10-May-04	160bp	17 trading days
8-Mar-05	18-Apr-05	65bp	27 trading days
3-Oct-05	14-Oct-05	30bp	7 trading days
1-May-06	27-Jun-06	65bp	40 trading days
Average		80bp	23 trading days
22-Feb-07		18bp to date	17 trading days to date

Source: J P Morgan, Bloomberg, UBS estimates

Four, consensus EPS revisions remain strong and uniquely off a high base of EPS growth. As discussed in our AES of 2 March *India Underweight*, the trend in consensus EPS revisions remain strong. Chart 3 highlights that 2007E consensus EPS has been upgraded by 10.1% since 31 December 2005. **More importantly, recent months have continued to be strong – with an upgrade of 2.4% in February alone and a further 0.6% upgrade so far in March.**

Chart 3: India 2007E consensus EPS


4th reason – strong consensus EPS upgrades



Source: IBES, UBS estimates


However, investors point out that strong consensus EPS upgrades are not unique to India. There are many other markets – such as China, Philippines, Singapore and Malaysia – which are also associated with strong consensus EPS upgrades. Chart 3-4 highlight that 2007 consensus EPS estimates since 31 December 2005 have been revised up by almost 19% in Singapore and by 10% in Malaysia.

Chart 2: 2007E consensus EPS - Singapore



Source: IBES, UBS estimates

Chart 3: 2007E consensus EPS - Malaysia



Source: IBES, UBS estimates

The key point for us though is while other markets are also associated with a strong uptrend in consensus EPS revisions, only India has a strong uptrend from a high EPS growth number in the first place.

Table 2 highlights that UBS bottom up estimates are for Indian EPS growth of 26% in 2007 and 23% in 2008. Singapore maybe associated with a strong uptrend but off a low base – just 6% EPS growth in 2007E. Even if we adjust for one-offs, Singapore’s EPS growth in 2007 is estimated to be between 13-14%.

UBS bottom up EPS growth in India for 2007E is 26% vs 6% for Singapore, 17% for Malaysia and 15% for the Philippines

We are funding the India upgrade from Singapore.

Table 1: Pre-exceptional EPS growth

Pre-ex EPS Growth								
Countries	2001	2002	2003	2004	2005	2006E	2007E	2008E
China (H-shares)	-18.7%	1.9%	48.2%	48.5%	14.4%	19.7%	19.7%	12.8%
Hong Kong (HSI)	-11.3%	5.4%	9.4%	19.4%	14.6%	18.9%	13.4%	15.5%
India	11.5%	20.2%	25.0%	23.3%	24.5%	34.2%	26.2%	22.9%
Indonesia	-23.7%	-11.5%	2.7%	32.8%	-3.8%	21.1%	37.0%	13.5%
Korea	6.6%	64.4%	-6.2%	71.6%	-1.3%	-8.1%	24.4%	10.5%
Malaysia	0.8%	32.0%	18.4%	5.4%	3.7%	18.8%	16.7%	9.4%
Philippines	57.7%	-18.3%	107.8%	45.8%	23.8%	10.6%	14.8%	12.4%
Singapore	-40.1%	24.6%	28.5%	43.7%	11.0%	21.6%	6.0%	15.2%
Taiwan	-81.0%	83.2%	57.0%	59.3%	-12.0%	9.1%	21.4%	12.9%
Thailand	nm	58.7%	36.7%	55.2%	14.5%	-8.0%	9.0%	9.5%
Asia ex-JP	-17.8%	26.2%	18.8%	40.5%	8.3%	11.0%	19.3%	14.0%

Source: UBS estimates

■ Statement of Risk

There are many risks in upgrading India from Underweight to Neutral. One, EMBI sell-off could continue for longer than we think. Two, macro tightening by the RBI may have further to go. Three, potential supply. Four, EPS growth and ROE are forecast to slow in 2008.

■ Analyst Certification

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

Required Disclosures

This report has been prepared by UBS Securities Pte. Ltd., an affiliate of UBS AG (UBS).

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures.

UBS Investment Research: Global Equity Ratings Definitions and Allocations

UBS rating	Definition	UBS rating	Definition	Rating category	Coverage ¹	IB services ²
Buy 1	FSR is > 6% above the MRA, higher degree of predictability	Buy 2	FSR is > 6% above the MRA, lower degree of predictability	Buy	44%	36%
Neutral 1	FSR is between -6% and 6% of the MRA, higher degree of predictability	Neutral 2	FSR is between -6% and 6% of the MRA, lower degree of predictability	Hold/Neutral	43%	36%
Reduce 1	FSR is > 6% below the MRA, higher degree of predictability	Reduce 2	FSR is > 6% below the MRA, lower degree of predictability	Sell	13%	26%

1: Percentage of companies under coverage globally within this rating category.

2: Percentage of companies within this rating category for which investment banking (IB) services were provided within the past 12 months.

Source: UBS. Ratings allocations are as of 31 December 2006.

KEY DEFINITIONS

Forecast Stock Return (FSR) is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months.

Market Return Assumption (MRA) is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium).

Predictability Level The predictability level indicates an analyst's conviction in the FSR. A predictability level of '1' means that the analyst's estimate of FSR is in the middle of a narrower, or smaller, range of possibilities. A predictability level of '2' means that the analyst's estimate of FSR is in the middle of a broader, or larger, range of possibilities.

Under Review (UR) Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation.

EXCEPTIONS AND SPECIAL CASES

US Closed-End Fund ratings and definitions are: Buy: Higher stability of principal and higher stability of dividends; Neutral: Potential loss of principal, stability of dividend; Reduce: High potential for loss of principal and dividend risk.

UK and European Investment Fund ratings and definitions are: Buy: Positive on factors such as structure, management, performance record, discount; Neutral: Neutral on factors such as structure, management, performance record, discount; Reduce: Negative on factors such as structure, management, performance record, discount.

Core Banding Exceptions (CBE): Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Companies Mentioned or Company Disclosure table in the relevant research piece.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report.

Global Disclaimer

This report has been prepared by UBS Securities Pte. Ltd., an affiliate of UBS AG (UBS). In certain countries UBS AG is referred to as UBS SA.

This report is for distribution only under such circumstances as may be permitted by applicable law. It has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. It is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, except with respect to information concerning UBS AG, its subsidiaries and affiliates, nor is it intended to be a complete statement or summary of the securities, markets or developments referred to in the report. The report should not be regarded by recipients as a substitute for the exercise of their own judgement. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS as a result of using different assumptions and criteria. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthesizing and interpreting market information. UBS is under no obligation to update or keep current the information contained herein. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS, into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this report is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues, however, compensation may relate to the revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part.

The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates and other market conditions. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. For investment advice, trade execution or other enquiries, clients should contact their local sales representative. Neither UBS nor any of its affiliates, nor any of UBS' or any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report. **Additional information will be made available upon request.**

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC and/or UBS Capital Markets LP) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this research report.

United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is communicated by UBS Limited, a subsidiary of UBS AG, to persons who are market counterparties or intermediate customers (as detailed in the FSA Rules) and is only available to such persons. The information contained herein does not apply to, and should not be relied upon by, private customers. UBS Limited is regulated by the FSA. **France:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France SA. UBS Securities France S.A. is regulated by the the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this report, the report is also deemed to have been prepared by UBS Securities France S.A. **Germany:** Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). **Spain:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). **Russia:** Prepared and distributed by the Moscow Representative Office of UBS Cyprus Moscow Limited. **Switzerland:** Distributed by UBS AG to persons who are institutional investors only. **Italy:** Prepared by UBS Limited and distributed by UBS Limited and UBS Italia Sim S.p.A.. UBS Italia Sim S.p.A. is regulated by the Bank of Italy and by the Commissione Nazionale per le Società e la Borsa (CONSOB). Where an analyst of UBS Italia Sim S.p.A. has contributed to this report, the report is also deemed to have been prepared by UBS Italia Sim S.p.A.. **South Africa:** UBS South Africa (Pty) Limited (Registration No. 1995/011140/07) is a member of the JSE Limited, the South African Futures Exchange and the Bond Exchange of South Africa. UBS South Africa (Pty) Limited is an authorised Financial Services Provider. **United States:** Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a "non-US affiliate"), to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a report prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this report must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. **Canada:** Distributed by UBS Securities Canada Inc., a subsidiary of UBS AG and a member of the principal Canadian stock exchanges & CIPF. A statement of its financial condition and a list of its directors and senior officers will be provided upon request. **Hong Kong:** Distributed by UBS Securities Asia Limited. **Singapore:** Distributed by UBS Securities Pte. Ltd or UBS AG, Singapore Branch. **Japan:** Distributed by UBS Securities Japan Ltd to institutional investors only. **Australia:** Distributed by UBS AG (Holder of Australian Financial Services Licence No. 231087) and UBS Securities Australia Ltd (Holder of Australian Financial Services Licence No. 231098) only to "Wholesale" clients as defined by s761G of the Corporations Act 2001. **New Zealand:** Distributed by UBS New Zealand Ltd.

© 2007 UBS. All rights reserved. This report may not be reproduced or redistributed, in whole or in part, without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect.